News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. »Lab282« Awarded First Projects. Oxford University and Evotec's Drug D

»Lab282« Awarded First Projects. Oxford University and Evotec's Drug Discovery Partnership Launched Last November to Accelerate Drugs to Market Begins Making Awards21/02/2017- Oxford University and Evotec's drug discovery partnership launched last November to accelerate drugs to market begins making awardsEvotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford Univer


2. Apollo Therapeutics – Funding of Four Initial Projects and Operational

Apollo Therapeutics – Funding of Four Initial Projects and Operational Update22/02/2017> First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities> Recruited highly experienced Project Directors with track records of delivering project success within big pharma> More than £8.5m committed to projects so far from a total budget of £40mApollo Therapeutics (


3. Positive Results for Relvar Ellipta Lung Function Study in Patients wi

Positive Results for Relvar Ellipta Lung Function Study in Patients with Well-controlled Asthma23/02/2017GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) c


4. Napp Launches Truxima (rituximab), the First Biosimilar Monoclonal Ant

Napp Launches Truxima (rituximab), the First Biosimilar Monoclonal Antibody for the Treatment of Cancer, in the UK24/02/2017Following European Medicines Agency (EMA) approval, the Medicines & Healthcare Products Regulatory Agency (MHRA) has authorised Truxima®, a biosimilar of rituximab, for use – making it the first biosimilar monoclonal antibody licensed for the treatment of cancer.1,2Truxima® is licensed for the treatment of conditions including non-Hodgkin lymphoma, chron


5. ZS-9 (sodium zirconium cyclosilicate) Receives Positive CHMP Opinion f

ZS-9 (sodium zirconium cyclosilicate) Receives Positive CHMP Opinion for the Treatment of Hyperkalaemia24/02/2017AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia, a serious condition characterised by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic



Page 21 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019